Search clinical trials for: TNX-102 SL Tablet, 2.8mg

Total 360 results

Tonix Pharmaceuticals, Inc.

Completed

A Phase 2 Study to Evaluate the Efficacy and Safety of TNX-102 SL in Patients With Multi-Site Pain Associated With Post-Acute Sequelae of SARS-CoV-2 Infection (PREVAIL)

COVID-19 | Long COVID | Post-Acute Sequelae of SARS-CoV-2 (PASC) Infection | Long Haul COVID

United States
Tonix Pharmaceuticals, Inc.

Completed

A Phase 3 Study to Evaluate the Efficacy and Safety of TNX-102 SL Taken Daily in Patients With Fibromyalgia (RESILIENT)

Fibromyalgia

United States
Tonix Pharmaceuticals, Inc.

Completed

Safety and Efficacy Study of TNX-102 SL in Subjects With Military-Related PTSD and Related Conditions (AtEase)

PTSD

United States
Tonix Pharmaceuticals, Inc.

Completed

A Study to Evaluate eFFIcacy and Safety of Sublingual TNX-102 SL Tablet Taken at Bedtime in Patients With fibRoMyalgia (AFFIRM)

Nervous System Diseases | Musculoskeletal Diseases | Rheumatic Diseases | Muscular Diseases | Neuromuscular Diseases | Fibromyalgia | Myofascial Pain Syndromes

United States
Tonix Pharmaceuticals, Inc.

Completed

Comparative Pharmacokinetics and Safety of 3 Different Formulations of TNX-102 2.8 mg SL Tablets and Cyclobenzaprine 5 mg Oral Tablet in Healthy Adults

Healthy Adults

Canada
Tonix Pharmaceuticals, Inc.

Completed

Comparative Pharmacokinetics and Safety of TNX-102 SL Tablets and Cyclobenzaprine Oral Tablet in Healthy Adults

Healthy Adults

Canada
Tonix Pharmaceuticals, Inc.

Terminated

A Phase 3 Study to Evaluate the Efficacy and Safety of TNX-102 SL in Participants With PTSD (RECOVERY)

PTSD

United States
Tonix Pharmaceuticals, Inc.

Terminated

Repeat of: A Study to Evaluate Efficacy and Safety of Sublingual TNX-102 SL Tablet Taken at Bedtime in Patients With Fibromyalgia (RE-AFFIRM)

Nervous System Diseases | Musculoskeletal Diseases | Rheumatic Diseases | Muscular Diseases | Neuromuscular Diseases | Fibromyalgia | Myofascial Pain Syndromes

United States
Tonix Pharmaceuticals, Inc.

Completed

A Study To Evaluate The Efficacy And Safety Of TNX-102 SL In Patients With Fibromyalgia (RELIEF)

Fibromyalgia

United States
Tonix Pharmaceuticals, Inc.

Completed

A Phase 3 Study To Evaluate The Efficacy And Safety Of TNX-102 SL In Patients With Fibromyalgia (RALLY)

Fibromyalgia

United States
Tonix Pharmaceuticals, Inc.
Premier Research Group plc

Terminated

Safety and Efficacy Study of TNX-102 SL in Patients With Military-related PTSD (HONOR)

PTSD

United States
Tonix Pharmaceuticals, Inc.

Completed

BEdtime Sublingual TNX-102 SL as Fibromyalgia Intervention Therapy (BESTFIT) (BESTFIT)

Primary Fibromyalgia

United States
Tonix Pharmaceuticals, Inc.

Completed

A 40-week Study to Evaluate TNX-102 SL 5.6 mg Taken Daily at Bedtime in Patients With PTSD (P306)

PTSD

United States
Hevert-Arzneimittel GmbH & Co. KG

Completed

Efficacy and Safety of Sinusitis Hevert SL Tablets Compared to Placebo in Adult Patients With Acute, Uncomplicated Rhinosinusitis (CESAR)

Acute Rhinosinusitis

Germany
Tonix Pharmaceuticals, Inc.

Terminated

A 3-Month Open-Label Safety and Efficacy Study of TNX-102 SL Tablets in Fibromyalgia Patients

Primary Fibromyalgia

United States
Tonix Pharmaceuticals, Inc.

Withdrawn

Safety and Efficacy Study of TNX-102 SL in Participants With PTSD

PTSD

Kenya
Tonix Pharmaceuticals, Inc.

Completed

Comparative Bioavailability of Sublingual TNX-102, Oral and Intravenous Cyclobenzaprine in Healthy Adults

Healthy Adults

Canada
Tenax Therapeutics, Inc.
Medpace, Inc.

Recruiting

LEVosimendan to Improve Exercise Limitation in Patients With PH-HFpEF (LEVEL)

Pulmonary Hypertension

United States
Engrail Therapeutics INC

Recruiting

ENCALM: A Study of ENX-102 as a Monotherapy Treatment in Patients With Generalized Anxiety Disorder (ENCALM)

Generalized Anxiety Disorder

United States
OrthoTrophix, Inc

Completed

A Study Evaluating the Safety and Efficacy of Intra-articular Injections of TPX-100 in Subjects With Mild to Moderate Patello-Femoral Osteoarthritis Involving Both Knees

Knee Osteoarthritis

United States
Tonix Pharmaceuticals, Inc.

Completed

Open Label Extension Safety and Efficacy Study of TNX-102 SL Tablets in Military Related PTSD and Related Conditions (P202)

PTSD

United States
Tonix Pharmaceuticals, Inc.

Completed

Dose-Proportionality and Food Effect Study of TNX-102 SL

Healthy Subjects

Canada
Tonix Pharmaceuticals, Inc.

Completed

12-Month Open-Label Long-term Safety Study of TNX-102 SL Tablets in Fibromyalgia Patients (BESTFIT-OLE)

Primary Fibromyalgia

United States
Tonix Pharmaceuticals, Inc.
Premier Research Group plc

Terminated

12-Week Open-Label Extension Study of TNX-102 SL in PTSD Patients

PTSD

United States
Saol Therapeutics Inc

Active, not recruiting

Phase II Study to Assess Safety and Efficacy of SL-1002 for Osteoarthritic Knee Pain (COMPASS)

Osteoarthritis, Knee Pain

United States
Saol Therapeutics Inc

Active, not recruiting

Phase II Study to Assess Safety, Pharmacokinetics and Efficacy of SL-1002 for Limb Spasticity (RAISE)

Spasticity

United States
Engrail Therapeutics INC

Withdrawn

ENACT: A Study of ENX-101 as Adjunctive Treatment in Patients With Focal Seizures (ENACT)

Focal Epilepsy

United States
Braeburn Pharmaceuticals

Completed

Clinical Trial of CAM2038, Long-acting Subcutaneous Buprenorphine Injections for Treatment of Patients With Opioid Dependence

Opioid Use Disorders

United States
Synchroneuron Inc.

Withdrawn

Trial of Oral SNC-102 in Subjects With Combat-Related Posttraumatic Stress Disorder (PTSD)

Posttraumatic Stress Disorders | Stress Disorders, Post-Traumatic | Post-Traumatic Stress Disorders | Post-Traumatic Stress Disorders, Combat-related
OrthoTrophix, Inc

Completed

A Study Evaluating the Safety and Efficacy of a Second Course of TPX-100 in Subjects Who Previously Received TPX-100 for Patellar Osteoarthritis Involving Both Knees

Knee Osteoarthritis
OrthoTrophix, Inc

Completed

A Prospective Observational Study to Evaluate Long-term Changes in Cartilage Morphology in Subjects Who Previously Received TPX-100 or Placebo in Study TPX-100-1 for Patellar Osteoarthritis Involving Both Knees

Mild to Moderate Knee OA

United States
Taiho Oncology, Inc.

Completed

Study Comparing the Bioavailability of TAS-102 Tablets to an Oral Solution Containing Equivalent Amounts of FTD and TPI

Advanced Solid Tumors (Excluding Breast Cancer)

United States
The First Affiliated Hospital with Nanjing Medical...
Guangzhou Lupeng Pharmaceutical Company LTD.; Newave Pharmaceutical Inc

Recruiting

A Phase I Study of LP-108 in Patients With Relapsed or Refractory B-cell Lymphoma

Chronic Lymphocytic Leukemia | Non-Hodgkin Lymphoma

China
Nanjing Sanhome Pharmaceutical, Co., Ltd.

Recruiting

SH-1028 Tablets Versus Placebo as Adjuvant Therapy in Resected Stage II-IIIB NSCLC With Sensitizing EGFR Mutations

Non-small Cell Lung Cancer

China
Alto Neuroscience

Completed

ALTO-100 in MDD and/or PTSD

Post Traumatic Stress Disorder | Major Depressive Disorder

United States
Alto Neuroscience

Completed

Pilot Decentralized Trial

Major Depressive Disorder

United States
Dong-A ST Co., Ltd.

Completed

A Clinical Trial to Compare the Pharmacokinetics of Imatinib Mesylate Tablet 400mg (1 Tablet) and Glivec Film-coated Tablet 100mg (4 Tablets)(Phase I)

Chronic Myeloid Leukemia | Gastrointestinal Stromal Tumor

Korea, Republic of
Cassava Sciences, Inc.
National Institute on Aging (NIA)

Completed

PTI-125 for Mild-to-moderate Alzheimer's Disease Patients

Alzheimer Disease

United States
InQpharm Group

Completed

Safety and Efficacy of IQP-LH-101 in Postprandial Heartburn

Postprandial Heartburn

Germany
Tego Science, Inc.

Completed

Safety and Efficacy Study of TPX-105 for Correction of Nasojugal Groove

Tear Trough Eyelid Deformity

Korea, Republic of
Pinotbio, Inc.

Completed

Safety and Tolerability of NTX-101 in Korean Healthy Volunteers

Healthy Volunteers

Korea, Republic of
Nanjing Sanhome Pharmaceutical, Co., Ltd.

Unknown

Pharmacokinetic Study of SH-1028 Tablets in Healthy Subjects Under Fasting and Fed Conditions

Healthy Volunteer
AstraZeneca

Completed

PET Study in Parkinson's Disease Patients

Parkinson's Disease

Sweden
TaiwanJ Pharmaceuticals Co., Ltd

Unknown

A Pharmacokinetic Study of JKB-122 Tablets Compared to Capsule

Autoimmune Hepatitis
Shanghai Leadingtac Pharmaceutical Co., Ltd.

Not yet recruiting

A Phase 1 Study of LT-002-158 Intended for the Treatment of Skind Disorder in Healthy Adult Volunteers

Atopic Dermatitis | Healthy Volunteer | Hidradenitis Suppurativa
Valenta Pharm JSC

Completed

Study of the Effect of Food Intake on the Bioavailability of XC221 100 mg Tablets

Healthy

Russian Federation
Point Therapeutics

Completed

Study of Talabostat in Advanced Melanoma

Melanoma | Skin Cancer

United States
Tonix Pharmaceuticals, Inc.

Completed

Steady-State Pharmacokinetic Comparison Study of TNX-102 SL 5.6 mg Versus AMRIX® 30 mg ER Capsules

Healthy Subjects

Canada
Atriva Therapeutics GmbH
SGS Life Sciences, a division of SGS Belgium NV

Completed

Phase 1 Study of ATR-002

Influenza

Belgium
Pain Therapeutics
National Institute on Aging (NIA)

Completed

PTI-125 for Mild-to-moderate Alzheimer's Disease Patients

Alzheimer Disease

United States

3

Subscribe